Activation of Toll‐like receptor 3 inhibits HIV infection of human iPSC‐derived microglia
Peng Wang,Jin‐Biao Liu,Xu Wang,Feng‐Zheng Meng,Qian‐Hao Xiao,Lu Liu,Jian Zhu,Wen‐Hui Hu,Wen‐Zhe Ho
DOI: https://doi.org/10.1002/jmv.29217
IF: 20.693
2023-11-08
Journal of Medical Virology
Abstract:As a key immune cell in the brain, microglia are essential for protecting the central nervous system (CNS) from viral infections, including HIV. Microglia possess functional Toll‐like receptor 3 (TLR3), a key viral sensor for activating interferon (IFN) signaling pathway‐mediated antiviral immunity. We, therefore, studied the effect of poly (I:C), a synthetic ligand of TLR3, on the activation of the intracellular innate immunity against HIV in human iPSC‐derived microglia (iMg). We found that poly (I:C) treatment of iMg effectively inhibits HIV infection/replication at both mRNA and protein levels. Investigations of the mechanisms revealed that TLR3 activation of iMg by poly (I:C) induced the expression of both type I and type III IFNs. Compared with untreated cells, the poly (I:C)‐treated iMg expressed significantly higher levels of IFN‐stimulated genes (ISGs) with known anti‐HIV activities (ISG15, MxB, Viperin, MxA, and OAS‐1). In addition, TLR3 activation elicited the expression of the HIV entry coreceptor CCR5 ligands (CC chemokines) in iMg. Furthermore, the transcriptional profile analysis showed that poly (I:C)‐treated cells had the upregulated IFN signaling genes (ISG15, ISG20, IFITM1, IFITM2, IFITM3, IFITM10, APOBEC3A, OAS‐2, MxA, and MxB) and the increased CC chemokine signaling genes (CCL1, CCL2, CCL3, CCL4, and CCL15). These observations indicate that TLR3 is a potential therapy target for activating the intracellular innate immunity against HIV infection/replication in human microglial cells. Therefore, further studies with animal models and clinical specimens are necessary to determine the role of TLR3 activation‐driven antiviral response in the control and elimination of HIV in infected host cells.
virology